Dubai Welcomes a Landmark Event in Animal Healthcare

On February 17th, 2025, The Grosvenor House in Marina Dubai became the epicenter of veterinary innovation as Nova Pharma, the distributor of Zoetis products in the region, hosted the Zoetis Launch Seminar. This premier event unveiled a trio of cutting-edge therapeutic monoclonal antibodies—Librela®, Solensia®, and Cytopoint®—heralding a transformative shift in the management of chronic conditions in companion animals. Attended by leading veterinarians, veterinary technicians, and industry professionals, the seminar underscored Zoetis’s unwavering commitment to advancing animal health through groundbreaking science and collaborative expertise.  

Innovation Meets Clinical Excellence  

The seminar highlighted Zoetis’s role as a trailblazer in biopharmaceutical solutions, emphasizing the critical intersection of research, education, and practical application. Attendees explored how these novel therapies are redefining standards of care for pets suffering from debilitating conditions like osteoarthritis and atopic dermatitis. By leveraging monoclonal antibody technology, Zoetis continues to bridge the gap between scientific discovery and real-world clinical impact, empowering veterinary teams to deliver targeted, long-lasting relief to their patients.  

Revolutionary Therapies Take Center Stage  

The seminar’s core focused on three innovative products poised to reshape veterinary practice:  

1. Librela® (bedinvetmab):  Offers monthly pain relief by targeting nerve growth factor (NGF), a key driver of chronic pain. This therapy enhances mobility and quality of life without the gastrointestinal risks associated with traditional NSAIDs.  
2. Solensia® (frunevetmab): As the first monoclonal antibody approved for feline osteoarthritis. Solensia effectively alleviates feline osteoarthritis pain for a whole month, with a proven safety profile.
3. Cytopoint® (lokivetmab): A trusted solution for canine atopic dermatitis, Cytopoint® manage pruritus (chronic itching) by neutralizing interleukin-31 (IL-31), providing rapid and sustained relief for dogs with allergic pruritus.

These therapies exemplify Zoetis’s mission to deliver precision medicine—treatments tailored to the unique biology of animals, minimizing side effects while maximizing efficacy.  

Insights from Global Leaders in Veterinary Medicine

The event featured illuminating presentations from renowned experts, blending clinical expertise with scientific rigor:  

– *Dr. Ignacio Calvo Nacho, EBVS® European Specialist in Small Animal Surgery, discussed the *clinical applications of monoclonal antibodies in managing chronic pain. He emphasized their potential to transform treatment protocols, particularly for aging pets with complex comorbidities.

– *Dr. Hilde Moyaert, Senior Director of Global Therapeutics at Zoetis, delved into the *decade-long journey of developing Librela® and Cytopoint®, highlighting rigorous safety trials and their proven success in improving patient outcomes worldwide.

– *Sara Shahin, Technical Manager for Companion Animals in the Middle East, provided actionable insights on *integrating these therapies into daily practice, stressing their ease of administration and role in strengthening client trust through measurable results.  

Collaboration Fuels Progress  

Beyond the scientific sessions, the seminar fostered meaningful connections during an evening of networking over cocktails and gourmet dining. Professionals exchanged experiences, debated emerging trends, and explored strategies to optimize the use of monoclonal antibodies in diverse clinical settings. These interactions underscored the importance of collaboration in driving the veterinary field forward, with many attendees expressing enthusiasm for future partnerships and knowledge-sharing initiatives.  

A Vision for the Future of Veterinary Care  

The Zoetis Launch Seminar was more than an educational event, it was a catalyst for change. By equipping veterinary teams with innovative tools and evidence-based strategies, Zoetis and Nova Pharma are paving the way for a future where chronic conditions no longer diminish the vitality of pets. As the industry embraces these advancements, continuous education and cross-disciplinary cooperation will remain essential to unlocking new possibilities in animal health.  

Closing Gratitude and Anticipation  

Nova Pharma and Zoetis extend their deepest appreciation to all attendees, speakers, and partners who contributed to the seminar’s success. Together, we are redefining what’s possible in veterinary medicine. Stay tuned for further updates on these transformative therapies, and join us in our mission to ensure every pet enjoys a life of comfort, joy, and longevity.  

Please contact your Nova Pharma Account Manager to learn more about Librela®, Solensia®, and Cytopoint®